Differential Effect Triggered by a Heparan Mimetic of the RGTA Family Preventing Oral Mucositis Without Tumor Protection

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1242-1250

  Mangoni, Monica ^a,b   Yue, Xiaoli ^c   Morin, Christophe ^c   Violot, Dominique ^a   Frascogna, Valerie ^a   Tao, Yungan ^a   Opolon, Paule ^a   Castaing, Marine ^a   Auperin, Anne ^a   Biti, Giampaolo ^b   Barritault, Denis ^d   Vozenin Brotons, Marie Catherine ^a   Deutsch, Eric ^a   Bourhis, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Université Paris 12 ^*  (France)

^d OTR3 SAS   (France)

Author keywords

Dextran derivative; Heparan mimetic; Radiation induced mucositis; Radioprotector; RGTA

Indexed keywords

AMIFOSTINE; CELL LINES; CLONOGENIC SURVIVAL; DIFFERENTIAL EFFECT; HEAD-AND-NECK CANCER; HEP-2 CELL LINES; HEPARAN; HEPARAN MIMETIC; HIGH DOSE; IN-VITRO; MUCOSITIS; NATURAL AGENTS; ORAL MUCOSITIS; PROTECTIVE EFFICACY; QUALITY OF LIFE; RADIATION-INDUCED MUCOSITIS; RADIOPROTECTOR; RGTA; SIDE EFFECT; SINGLE-DOSE; THERAPEUTIC SOLUTIONS; TUMOR CELLS; TUMOR GROWTH; TUMOR PROTECTION;

CELL CULTURE; DEXTRAN; GLUCOSE; IRRADIATION;

TUMORS;

AMIFOSTINE; DEXTRAN DERIVATIVE; OTR 4131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; TUMOR GROWTH; TUMOR XENOGRAFT;

AMIFOSTINE; ANIMALS; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCANS; HT29 CELLS; HUMANS; LIP; MICE; MICE, INBRED C57BL; MICE, NUDE; RADIATION DOSAGE; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RANDOM ALLOCATION; STOMATITIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649544662     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.006     Document Type: Article

References (33)

1. Sonis S.T. Mucositis as biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 (1998) 39-43
2. Mabro M., Faivre S., and Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 21 (1999) 367-387
3. Bensadoun R.J., Schubert M.M., Lalla R.V., and Keefe D. Amifostine in the management of radiation-induced and chemo-induced mucositis. Support Care Cancer 14 (2006) 566-572
4. Spielberger R., Stiff P., Besinger W., et al. Palifermin for oral mucositis after intensive therapy for hemathologic cancers. N Engl J Med 351 (2004) 2590-2598
5. Blanquaert F., Barritault D., Saffar J.L., et al. CMDBS, functional analogs of sulfate heparanes, used as osseous cicatrizing agents. Ann Endocrinol 55 (1994) 121-123
6. Meddahi A., Caruelle J.P., Gold L., et al. New concepts in tissue repair: Skin as an example. Diabetes Metab 22 (1996) 274-278
7. Desgranges P., Barbaud C., Caruelle J.P., et al. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 13 (1999) 761-766
8. Benoit J., Meddahi A., Ayoub N., et al. New healing agent for colonic anastomosis. Int J Colorectal Dis 13 (1998) 78-81
9. Escartin Q., Lallam-Laroye C., Baroukh B., et al. A new approach to treat tissue destruction in periodontitis with heparan mimetics. EMBO J 17 (2003) 644-651
10. Morvan O.F., Baroukh B., Ledoux D., et al. An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. Am J Pathol 164 (2004) 739-746
11. Papy-Garcia D., Barbier-Chassefiere V., Rouet V., et al. Nondegradative sulfatation of polysaccharides and structure characterization of biologically active heparansulfate mimetics. Macromolecules 38 (2005) 4647-4654
12. Parkins C.S., Fowler J.F., and Yu S. A murine model of lip epidermal/mucosal reactions to X-irradiation. Radiother Oncol 1 (1983) 159-165
13. Euhus D.M., Hudd C., LaRegina M.C., and Johnson F.E. Tumor measurement in the nude mice. J Surg Oncol 31 (1986) 229-234
14. Crowder M.J., and Hand D.J. Analysis of repeated measures (1990), Chapman & Hall, London
15. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomised trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
16. Boccia R., Anné P.R., Bourhis J., et al. Assessment and management of cutaneous reactions with amifostine administration: Findings of the Ethyol (amifostine) Cutaneus Treatment Advisory Panel (ECTAP). I J Rad Oncol Biol Phys 60 (2004) 302-309
17. Meddhai A., Lemdjabar H., Cartelle J.P., et al. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 18 (1996) 141-145
18. Ledoux D., Papy-Garcia D., Escartin Q., et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 275 (2000) 29383-29390
19. Ledoux D., Merciris D., Barritault D., and Caruelle J.P. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett 537 (2003) 23-29
20. Tardieu M., Gamby C., Avramoglou T., et al. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 150 (1992) 194-203
21. Worthington H.V., Clarkson J.E., and Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 4 (2007) CD000978
22. Alexakis C., Guettoufi A., Mestries P., et al. Heparan mimetic regulates collagen expression and TGF-β1 distribution in gamma-irradiated human intestinal smooth muscle cells. FASEB J 15 (2001) 1546-1554
23. Charef S., Petit E., Barritault D., et al. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally. J Biomed Mater Res A 83 (2007) 1024-1031
24. Rouet V., Meddahi-Pellé A., Miao H.Q., et al. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res A 78 (2006) 792-797
25. Alexakis C., Strup C., Mestries P., et al. Regulation of the collagen phenotype expression of gamma-irradiated vascular smooth muscle cells by heparan mimetics (RGTA). J Biomed Mater Res A 70 (2004) 594-602
26. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 24 (2006) 2873-2878
27. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
28. Budach W., Bölke E., and Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357 (2007) 514-515
29. Maggiorella L., Frascogna V., Poullain M.G., et al. The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis. Clin Cancer Res 7 (2001) 2091-2095
30. Wen B., Deutsch E., Marangoni E., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85 (2001) 2017-2021
31. Withers H.R., Thames Jr. H.D., and Peters L.J. A new isoeffect curve for change in dose per fraction. Radiother Oncol 1 (1983) 187-191
32. Dörr W., Bässler S., Reichel S., and Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): Experimental studies in mice. I J Rad Oncol Biol Phys 62 (2005) 881-887
33. Vuyyuri S.B., Hamstra D.A., Khanna D., et al. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res 14 (2008) 2161-2170